Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):281-294. doi: 10.1007/s00259-023-06392-0. Epub 2023 Aug 19.
The current clinical recommendations posit the deployment of specific approved radiolabeled prostate-specific membrane antigen-ligand positron emission tomography (PSMA PET) for detecting metastatic prostate cancer during primary staging. Nevertheless, the precise efficacy of such ligands in localizing intraprostatic tumours (index tumour) and T-staging is not well established. Consequently, the objective of this inquiry is to ascertain the diagnostic accuracy of PSMA-PET in the tumour staging of newly diagnosed prostate cancer by means of a meta-analysis that integrates studies utilizing histological confirmation as the reference standard.
In this study, we conducted a systematic literature search of the PubMed, Embase, Web of Science, and Cochrane Library databases using a predefined collection of search terms. These terms included 'PSMA PET', 'primary staging', and 'prostate cancer'. Subsequently, two independent reviewers evaluated all the studies based on predetermined inclusion criteria, extracted pertinent data, and assessed the quality of evidence. Any disparities were resolved by a third reviewer. A random effects Sidik-Jonkman model was applied to conduct a meta-analysis and estimate the diagnostic accuracy on a per-patient basis, along with 95% confidence intervals. Moreover, an appraisal regarding the likelihood of publication bias and the impact of small-study effects was performed utilizing both Egger's test and a graphical examination of the funnel plot.
The present analysis comprised a total of twenty-three scientific papers encompassing 969 patients and involved their analysis by both qualitative and quantitative approaches. The results of this study demonstrated that the estimated diagnostic accuracy of PSMA PET/CT and PSMA PET/MRI, for the detection of intraprostatic tumours, regardless of the type of PSMA-ligand, was 86% (95% CI: 76-96%) and 97% (95% CI: 94-100%), respectively. Furthermore, the diagnostic accuracy for the detection of extraprostatic extension (EPE) was 73% (95% CI: 64-82%) and 77% (95% CI: 69-85%), while the diagnostic accuracy for the detection of seminal vesicle involvement (SVI) was 87% (95% CI: 80-93) and 90% (95% CI: 82-99%), respectively.
The present investigation has demonstrated that PSMA PET/MRI surpasses currently recommended multiparametric magnetic resonance imaging (mpMRI) in terms of diagnostic accuracy as inferred from a notable data trajectory, whereas PSMA-PET/CT exhibited comparable diagnostic accuracy for intraprostatic tumour detection and T-staging compared to mpMRI. Nevertheless, the analysis has identified certain potential limitations, such as small-study effects and a potential for publication bias, which may impact the overall conclusions drawn from this study.
目前的临床推荐意见主张在初次分期时使用特定的经批准的放射性标记前列腺特异性膜抗原配体正电子发射断层扫描(PSMA PET)来检测转移性前列腺癌。然而,这些配体在定位前列腺内肿瘤(指数肿瘤)和 T 分期方面的确切效果尚未得到很好的确定。因此,本研究的目的是通过整合使用组织学确认为参考标准的研究的荟萃分析,确定 PSMA-PET 在新诊断前列腺癌肿瘤分期中的诊断准确性。
本研究通过预定义的搜索词集对 PubMed、Embase、Web of Science 和 Cochrane Library 数据库进行了系统的文献检索。这些术语包括“PSMA PET”、“初步分期”和“前列腺癌”。然后,两名独立的审查员根据预先确定的纳入标准评估所有研究,提取相关数据,并评估证据质量。任何分歧都由第三名审查员解决。应用随机效应 Sidik-Jonkman 模型进行荟萃分析,以基于每位患者的情况估计诊断准确性,并提供 95%置信区间。此外,还使用 Egger 检验和漏斗图的图形检查评估发表偏倚的可能性和小研究效应的影响。
本分析共包括 23 篇科学论文,涉及 969 名患者,并通过定性和定量方法对其进行了分析。研究结果表明,PSMA PET/CT 和 PSMA PET/MRI 检测前列腺内肿瘤的估计诊断准确性,无论 PSMA 配体类型如何,均为 86%(95%CI:76-96%)和 97%(95%CI:94-100%),分别。此外,检测前列腺外扩展(EPE)的诊断准确性为 73%(95%CI:64-82%)和 77%(95%CI:69-85%),而检测精囊腺侵犯(SVI)的诊断准确性为 87%(95%CI:80-93%)和 90%(95%CI:82-99%),分别。
本研究表明,PSMA PET/MRI 在诊断准确性方面优于目前推荐的多参数磁共振成像(mpMRI),这可以从明显的数据轨迹推断得出,而 PSMA-PET/CT 与 mpMRI 相比,在前列腺内肿瘤检测和 T 分期方面具有相当的诊断准确性。然而,该分析确定了一些潜在的局限性,例如小研究效应和发表偏倚的可能性,这可能会影响从这项研究中得出的总体结论。